Back to Search
Start Over
SMA - TREATMENT: EP.284 SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA).
- Source :
-
Neuromuscular Disorders . 2021 Supplement 1, Vol. 31, pS136-S136. 1p. - Publication Year :
- 2021
- Subjects :
- *SPINAL muscular atrophy
*PATIENT safety
Subjects
Details
- Language :
- English
- ISSN :
- 09608966
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Neuromuscular Disorders
- Publication Type :
- Academic Journal
- Accession number :
- 152517341
- Full Text :
- https://doi.org/10.1016/j.nmd.2021.07.309